Journal of Gastroenterology

, Volume 37, Supplement 14, pp 67–72

Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial

Authors

  • Osamu Kanauchi
    • Nutrient Food and Feed DivisionKirin Brewery
  • Toshihiro Suga
    • Sapporo Kosei General Hospital
  • Masahiro Tochihara
    • Sapporo Kosei General Hospital
  • Toshifumi Hibi
    • Keio University School of Medicine
  • Makoto Naganuma
    • Keio University School of Medicine
  • Terasu Homma
    • Niigata University School of Medicine
  • Hitoshi Asakura
    • Niigata University School of Medicine
  • Hiroshi Nakano
    • Fujita Health University School of Medicine
  • Kazuya Takahama
    • Fujita Health University School of Medicine
  • Yoshihide Fujiyama
    • Shiga University of Medical Science
  • Akira Andoh
    • Shiga University of Medical Science
  • Takashi Shimoyama
    • Hyogo College of Medicine
  • Nobuyuki Hida
    • Hyogo College of Medicine
  • Ken Haruma
    • Kawasaki Medical School
  • Hideki Koga
    • Kawasaki Medical School
  • Keiichi Mitsuyama
    • Kurume University School of Medicine
  • Michio Sata
    • Kurume University School of Medicine
  • Masanobu Fukuda
    • Kirin Brewery
  • Atsushi Kojima
    • Kirin Brewery
  • Tadao Bamba
    • Shiga University of Medical Science
Biotherapy and biological response modifiers for IBD

DOI: 10.1007/BF03326417

Cite this article as:
Kanauchi, O., Suga, T., Tochihara, M. et al. J Gastroenterol (2002) 37: 67. doi:10.1007/BF03326417

Abstract

Background. Germinated barley foodstuff (GBF) is a prebiotic foodstuff that effectively increases luminal butyrate production by stimulating the growth of protective bacteria. In the first pilot study, GBF has been shown to reduce both clinical activity and mucosal inflammation in ulcerative colitis (UC). The aim of this study was to investigate the efficacy of GBF in the treatment of UC in a multicenter open control trial. Methods. Eighteen patients with mildly to moderately active UC were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20–30 g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal micro-flora were also analyzed. Results. After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum. Conclusions. Oral GBF therapy may have the potency to reduce clinical activity of UC. We believe that these results support the use of GBF administration as a new adjunct therapy for UC.

Keywords

prebiotics probiotic ulcerative colitis microflora

Copyright information

© Springer-Verlag 2002